Monitor for interim Phase 2 data from the RENEW trial in H2 2026, which is the next major catalyst. The $57.5M offering removes near-term dilution risk and provides runway through Q1 2028, reducing financing overhang.
Price Chart
Executive Summary
Rein Therapeutics reported Q2 2026 GAAP EPS of -$0.10, beating consensus of -$0.27 by 63%, driven by lower operating expenses. The key catalysts are clinical progress in the Phase 2 RENEW trial (LTI-03 for IPF) with enrollment ahead of schedule and interim data expected H2 2026, plus a $57.5M public offering that extends cash runway into Q1 2028.
Key Financial Metrics
Key Facts
- GAAP EPS -$0.10 vs consensus -$0.27 (63% beat)
- Surpassed 25% enrollment in Phase 2 RENEW trial (LTI-03 for IPF); interim data expected H2 2026
- Completed oversubscribed $57.5M public offering, fully funding the trial into Q1 2028
- Cash, cash equivalents and marketable securities of $43.6M as of June 30, 2026
- Net loss of $6.4M in Q2 2026 vs $6.8M in Q2 2025
Financial Impact
EPS beat of $0.17 vs consensus loss of $0.27, but pre-revenue biotech; clinical progress and strengthened balance sheet are the primary drivers
Risk Factors
- Clinical trial failure or disappointing interim data could severely impact stock
- Future dilution if additional capital is needed beyond Q1 2028
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345214 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 7w ago | Press Release | $0.8891 | awaiting T+60 | — | $0.5832 (−34.41%) |
Aug 14, 2026 10w ago | Press Release | $0.8060 | awaiting T+60 | — | $0.5832 (−27.64%) |
Jul 21, 2026 13w ago | Press Release | $0.8948 $0.7546 | ▼ −15.67% | ▼ −19.64% | $0.5832 (−34.82%) |
Jun 8, 2026 20w ago | DEFA14A | $0.9487 $0.7527 | ▼ −20.66% | ▼ −23.71% | $0.5832 (−38.53%) |
May 4, 2026 25w ago | 8-K | $1.02 $0.7680 | ▲ +24.71% | ▲ +27.45% | $0.5832 (+42.82%) |
May 4, 2026 25w ago | 424B5 | $1.02 $0.7580 | ▲ +25.69% | ▲ +27.54% | $0.5832 (+42.82%) |
May 1, 2026 25w ago | Press Release | $1.03 $0.7818 | ▲ +24.10% | ▲ +27.17% | $0.5832 (+43.38%) |
Apr 29, 2026 25w ago | Press Release | $1.28 $0.7913 | ▼ −37.94% | ▼ −42.05% | $0.5832 (−54.26%) |
Apr 28, 2026 25w ago | S-1 | $1.28 $0.7913 | ▼ −37.94% | ▼ −42.05% | $0.5832 (−54.26%) |
Apr 27, 2026 26w ago | 10-K/A | $1.49 $0.8400 | ▼ −43.62% | ▼ −48.40% | $0.5832 (−60.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers